The EPO published EP3700518A1 on March 25, 2026, granting Amarin Pharmaceuticals Ireland Limited patent protection for methods of reducing cardiovascular events using icosapent ethyl. The patent application, filed by inventor Paresh SONI, includes claims covering compositions and methods under multiple IPC classifications including A61K31/232 and A61P9/10 (cardiovascular). Designation extends to 31 European states including AT, BE, DE, ES, FR, GB, IT, NL, PL, and others.\n\nPharmaceutical companies and investors should review the patent claims to assess potential market exclusivity implications for icosapent ethyl products in designated EU states. Generic manufacturers and competitors developing cardiovascular treatments should evaluate freedom-to-operate considerations. The patent provides Amarin with enforceable exclusivity rights, though no compliance obligations are imposed on third parties by this publication.